Deferring systemic therapy may improve survival outcomes in carefully selected patients with metastatic renal cell carcinoma, new data suggest.

Hepatocellular carcinoma (HCC) management is rapidly evolving as systemic therapies and locoregional treatments are increasingly combined across disease ...

(RTTNews) - Citius Oncology, Inc. (CTOR), the oncology subsidiary of Citius Pharmaceuticals Inc. (CTXR) announced the U.S. commercial launch of LYMPHIR, a new immunotherapy for adults with relapsed or ...

A University of Kentucky Markey Cancer Center study shows that a targeted form of radiation therapy can be safely delivered ...

Serial metastasis-directed radiotherapy extended time off systemic therapy while maintaining favorable progression-free and overall survival in patients with oligometastatic clear-cell renal cell ...

Severe alopecia areata may be driven by broader immune activation than previously recognized, according to new research ...